eligibility_summary
Eligibility: Adults ≥18 with high‑risk LBCL (IPI 3–5 and/or double/triple‑hit), PET‑positive after ≥2 cycles CD20+anthracycline, ECOG 0–1, expected survival >12 wks, adequate counts/renal/hepatic function, LVEF ≥50%, SpO2 >92%, vascular access, contraception. Exclude CNS lymphoma, other cancer not in ≥2‑yr remission, active HBV/HCV/HIV/syphilis or infection, recent DVT/PE, GVHD, serious CV/CNS disease, pregnancy/nursing, prior HSCT/CAR‑T, live vaccine <6 wks, severe allergy.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Interventions: Relmacabtagene autoleucel (Relma-cel, JWCAR029), an autologous CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy, given as a single IV infusion, preceded by lymphodepleting chemotherapy with fludarabine (purine analog antimetabolite) and cyclophosphamide (alkylating agent). Mechanisms: T cells are genetically engineered to express a CAR that recognizes CD19 on B cells, CAR engagement activates T-cell signaling (CD3ζ with costimulation) to drive cytotoxic killing and cytokine-mediated clearance of malignant B cells, with expected on-target B-cell aplasia. Targets: CD19 on large B-cell lymphoma cells (B-cell lineage/BCR co-receptor pathway), effector cells are autologous T cells, lymphodepletion reduces endogenous lymphocytes to foster CAR-T expansion and persistence.